T Cell News and Research

Latest T Cell News and Research

Scientists identify new way to deliver long-lasting pain relief

Scientists at the University of North Carolina at Chapel Hill have identified a new way to deliver long-lasting pain relief through an ancient medical practice.

24 Apr 2012

Cadmium exposure can cause progression of aggressive breast cancer

Studies by researchers at Dominican University of California show that breast cancer cells become increasingly aggressive the longer they are exposed to small concentrations of cadmium, a heavy metal commonly found in cosmetics, food, water and air particles.

24 Apr 2012

Cancer therapy with common cold virus

Common viruses have become the latest weapon against cancer. There is the case of the eight-year-old African boy diagnosed with Burkitt's lymphoma at a Ugandan health clinic. He was exposed to the measles virus and in the next few weeks his tumour regressed completely and he entered remission. But only relatively recently have scientists clinically examined the interaction between viruses and cancers in the growing area of oncolytic virotherapy.

24 Apr 2012

Study: hUC-MSCs reduce inflammation that causes colitis

When laboratory mice were modeled with colitis and treated with human umbilical cord-derived mesenchymal cells, the cells homed in on the inflamed colon and effectively ameliorated colitis, reported a study published in a recent issue of Cell Transplantation.

24 Apr 2012

TopBP1 protein prevents early brain cells from DNA damage

St. Jude Children's Research Hospital scientists have rewritten the job description of the protein TopBP1 after demonstrating that it guards early brain cells from DNA damage. Such damage might foreshadow later problems, including cancer.

24 Apr 2012

Novel technological treatment for Leber Hereditary Optic Neuropathy

A research team, led by John Guy, M.D., professor of ophthalmology at Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine, has pioneered a novel technological treatment for Leber Hereditary Optic Neuropathy (LHON), an inherited genetic defect that causes rapid, permanent, and bilateral loss of vision in people of all ages, but primarily males ages 20-40.

24 Apr 2012

HDAC6 protein may provide novel target for stress-linked disorders

A cellular protein called HDAC6, newly characterized as a gatekeeper of steroid biology in the brain, may provide a novel target for treating and preventing stress-linked disorders, such as depression and post-traumatic stress disorder (PTSD), according to research from the Perelman School of Medicine at the University of Pennsylvania.

24 Apr 2012

Researchers identify gene that increases risk of MI in newborns with CF

Researchers at Johns Hopkins have identified a gene that modifies the risk of newborns with cystic fibrosis (CF) developing neonatal intestinal obstruction, a potentially lethal complication of CF.

24 Apr 2012

IGF1R-blocking drugs can treat children with Wilms' tumour

An experimental drug that blocks an essential cell protein could be used to treat Wilms' tumour, a childhood cancer that affects the kidneys.

24 Apr 2012

FDA issues draft guidelines on approval process for use of nanoparticles in food and cosmetics

The United States Food and Drugs Administraton (FDA) has proposed that food companies that want to use tiny engineered particles called nanoparticles in their packaging may have to provide extra testing data to show the products are safe.

23 Apr 2012

Phytochemicals in mangos may target breast cancer cells

Already one of the world's most popular fruits, scientists are discovering that mangos may also be one of the healthiest. New research, presented this week at the Federation of American Societies for Experimental Biology (FASEB) meeting in San Diego, not only suggests people who eat mangos have a better diet, but the fruit also contains a substance that may have an effect on breast cancer cell proliferation.

23 Apr 2012

Brain injury in amateur boxing similar to Alzheimer´s

Olympic boxers can exhibit changes in brain fluids after bouts, which indicates nerve cell damage. This is shown in a study of 30 top-level Swedish boxers that was conducted at the Sahlgrenska Academy at the University of Gothenburg, Sweden, in collaboration with the Swedish Boxing Federation, published in PLoS ONE.

23 Apr 2012

Method to manufacture cartilage from human embryonic stem cells

BioTime, Inc. and its wholly owned subsidiary OrthoCyte Corporation reported today a means of manufacturing cartilage from human embryonic stem cells that is suited for industrial scale-up of a product for the treatment of osteoarthritis.

23 Apr 2012

Cancer, genetic screenings under scrutiny

Various news outlets covered issues around cancer screening, diagnosis and treatment.

23 Apr 2012

Asubio commences SUN13837 Phase 2 clinical trial for acute spinal cord injury

Today, Asubio announced the initiation of a landmark Phase 2 clinical trial of SUN13837, an investigational medication being developed to improve neurological function in patients with newly diagnosed acute spinal cord injury.

23 Apr 2012

NEI awards Scripps Research $10.2M grant to develop new treatments for vision disorders

A team led by a scientist from The Scripps Research Institute has been awarded a five-year, $10.2 million grant from the National Eye Institute (NEI) to develop a new type of treatment for diabetic retinopathy, macular degeneration, and other common vision disorders.

23 Apr 2012

Nano-devices cross blood-brain barrier to deliver drug to treat cerebral palsy

A team of scientists from Johns Hopkins and elsewhere have developed nano-devices that successfully cross the brain-blood barrier and deliver a drug that tames brain-damaging inflammation in rabbits with cerebral palsy.

23 Apr 2012

Intrinsically disordered protein responsible for inactivating BK channel

Tiny pores, or channels, embedded in cell membranes are critical to the healthy functioning of cells. Charged atoms, or ions, move through these channels to generate the electrical signals that allow cells to communicate with one another.

23 Apr 2012

OncoSec reports positive interim data from ElectroChemotherapy Phase IV head and neck cancer study

OncoSec Medical Inc., which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, today announced positive interim analysis of data from 81 subjects in a Phase IV study of primary and locally recurrent squamous cell carcinoma of the head and neck (HNSCC) treated with OMS ElectroChemotherapy in Europe.

23 Apr 2012

First Edition: April 23, 2012

Today's headlines feature advance information about what the trustees who oversee Medicare and Social Security will say about the financial well-being of these massive programs when they release their annual report later today.

23 Apr 2012